method
Reverse phase flash chromatography effectively separates cannabinoids with similar properties, producing a formulation with high purity of the desired cannabinoid for consumer products.
Patent Information
- Application Number
- PCT/IB2026/054489
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Current remediation methods for cannabinoids are inadequate in separating cannabinoids with similar chemical structures and polarities, leading to unsuitable formulations for specific consumer products.
A method utilizing reverse phase flash chromatography to separate a first cannabinoid from a second cannabinoid, achieving a remediated formulation with the first cannabinoid at greater than 70w/w% and less than 0.5w/w% of the second cannabinoid.
Produces a remediated formulation with a high concentration of the desired cannabinoid and minimal presence of undesired cannabinoids, suitable for aerosolisable and ingestible materials.
Smart Images

Figure IB2026054489_12112026_PF_FP_ABST
Abstract
Description
[0001] WBDRef.No. B118615 1980WO (00125)
[0002] METHOD
[0003] Field of the Invention
[0004] The present invention relates to a method of producing a remediated formulation comprising a first cannabinoid, a remediated formulation obtained or obtainable by such a method, as well as an aerosolisable material and ingestible material comprising such remediated formulations.
[0005] Background
[0006] Cannabinoids are a group of naturally occurring compounds found in plants such as cannabis. In particular, the Cannabis sativa species expresses at least 120 different phytocannabinoids. Extracts can be prepared from the plant, and these extracts can contain multiple different cannabinoids. Several cannabinoids have been shown to have physiological effects, resulting in a demand for cannabinoid containing products. For example, tetrahydrocannabivarin (THCV) is thought to improve focus and energy. However, due to the extract typically containing a range of cannabinoids, and also that these cannabinoids can have different effects, it can be desirable to prepare formulations derived from the extracts which have a more selective cannabinoid profile.
[0007] Remediation is the process of removing one or more undesired components, such as one or more cannabinoids, from cannabis plant-derived extracts. The resulting remediated formulation can contain a more focussed cannabinoid, and therefore effect, profile which mean that the formulation is better suited to be used in a variety of products. Typical products including the formulation may include ingestible materials such as beverages or chews, and aerosolisable materials.
[0008] Current remediation methods may not be suitable for the separation of all components. For example, distillation may be unsuitable where the boiling points of the components to be separated are similar. Moreover, distillation can result in the removal of other components of the extract which may be desirably maintained. Crystallization may be unsuitable where the desired cannabinoid is amorphous.
[0009] Therefore, it would be desirable to provide improved methods of remediating certain cannabinoids.
[0010] Summary of the Invention
[0011] In one aspect, there is provided a method of producing a remediated formulation comprising a first cannabinoid, the method comprising remediating a starting formulation comprising the first cannabinoid and a second cannabinoid via reverse phase flash
[0012] chromatography.WBDRef.No. B118615 1980WO (00125)
[0013] ln one aspect, there is provided a remediated formulation obtained or obtainable by the methods described herein.
[0014] In one aspect, there is provided a formulation comprising a first cannabinoid in an amount of greater than 70w / w%, wherein the formulation comprises less than 0.5w / w% of a second cannabinoid, based on the total weight of the formulation.
[0015] In one aspect, there is provided an aerosolisable material comprising a remediated formulation obtained or obtainable by the methods described herein.
[0016] In one aspect, there is provided an aerosolisable material comprising a first cannabinoid in an amount of greater than 0.1w / w%, wherein the formulation comprises less than 0.5w / w% of a second cannabinoid, based on the total weight of the aerosolisable material.
[0017] In one aspect, there is provided an ingestible material comprising a remediated formulation obtained or obtainable by the methods described herein.
[0018] In one aspect, there is provided an ingestible material comprising a first cannabinoid in an amount of greater than 0.0001 w / w%, wherein the formulation comprises less than 0.5w / w% of a second cannabinoid, based on the total weight of the ingestible material.
[0019] In one aspect, there is provided a method of producing an aerosolisable material, the method comprising:
[0020] 1) preparing a remediated formulation according to the methods described herein;
[0021] 2) combining the remediated formulation with one or more aerosol forming materials.
[0022] In one aspect, there is provided a method of producing an ingestible material, the method comprising:
[0023] 1) preparing a remediated formulation according to the methods described herein;
[0024] 2) combining the remediated formulation with one or more emulsifiers.
[0025] These aspects and other aspects will be apparent from the following detailed description. Disclosures mentioned in the context of one aspect are not limited to that aspect, and may be applied to and / or combined with other disclosures mentioned throughout the description.
[0026] Brief Description of the Figures
[0027] Figure 1 provides a reverse phase flash chromatogram produced according to Example 1 ; and
[0028] Figure 2 provides a reverse phase flash chromatogram produced according to Example 2.
[0029] Detailed Description
[0030] In one aspect, there is provided a method of producing a remediated formulation comprising a first cannabinoid, the method comprising remediating a starting formulationWBDRef.No. B118615 1980WO (00125)
[0031] comprising the first cannabinoid and a second cannabinoid via reverse phase flash chromatography.
[0032] Remediation
[0033] The method described herein comprises remediating a starting formulation comprising the first cannabinoid and a second cannabinoid via reverse phase flash chromatography. Remediation is generally understood as any method or process that removes or reduces the level of a compound in a given formulation. In the context of the present disclosure, the second cannabinoid is remediated from a starting formulation comprising the first cannabinoid and second cannabinoid.
[0034] Starting Formulation
[0035] The starting formulation comprises a first cannabinoid and a second cannabinoid. Other cannabinoids and other components may also be present in the starting formulation.
[0036] Cannabinoids are a class of natural or synthetic chemical compounds, some of which are known to act on cannabinoid receptors (i.e., CB1 and CB2) in cells that repress neurotransmitter release in the brain. Other molecular targets of cannabinoids have been identified and are discussed in Ibeas Bih, C., Chen, T., Nunn, A. V.W. etal. Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics 12, 699-730 (2015).
[0037] Cannabinoids are cyclic molecules exhibiting particular properties such as the ability to easily cross the blood-brain barrier.
[0038] Cannabinoids may be naturally occurring (phytocannabinoids) from plants such as cannabis, (endocannabinoids) from animals, or artificially manufactured (synthesised cannabinoids).
[0039] Cannabis sativa species express at least 120 different phytocannabinoids (see ElSohly, M.A.; Radwan, M.M.; Gul, W.; Chandra, S.; Gala!, A. Phytochemistry of Cannabis sativa L. Prog. Chem. Org. Nat. Prod. 2017, 103, 1-36) , and these may be divided into subclasses, including cannabigerols, cannabichromenes, cannabidiols, tetrahydrocannabinols, cannabinols and cannabinodiols, and other cannabinoids, such as cannabigerol (CBG), cannabigerolic acid (CBGA), cannabichromene (CBC), cannabichromenic acid (CBCA), cannabidiol (CBD), cannabidolic acid (CBDA), tetrahydrocannabinol (THC), including its isomers A6a Wa-tetrahydrocannabinol (A6a’10a-THC), A6a(7)-tetrahydrocannabinol (A6a(7)-THC), A8-tetrahydrocannabinol (A8-THC), AMetrahydrocannabinol (A9-THC), A10-tetrahydrocannabinol (A10-THC), A9’11-tetrahydrocannabinol (A9 11-THC), tetrahydrocannabinolic acid (THCA), cannabinol (CBN), cannabinolic acid (CBNA), and cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), and cannabigerol monomethyl ether (CBGM).WBDRef.No. B118615 1980WO (00125)
[0040] Naturally occurring cannabinoids (phytocannabinoids) are generally present in raw plant material in their carboxylated form. These acids can be decarboxylated by moderate to high temperature (such as from heating or processing within an extraction process), UV exposure or prolonged storage to form the more physiologically active decarboxylated form. In this regard, cannabidiol (CBD) and cannabidolic acid (CBDA) are the respective decarboxylated and carboxylated forms of the same “cannabinoid”.
[0041] CBD
[0042]
[0043] In one embodiment, the first cannabinoid and the second cannabinoid are selected from cannabigerol (CBG), cannabigerolic acid (CBGA), cannabichromene (CBC), cannabichromenic acid (CBCA), cannabidiol (CBD), cannabidolic acid (CBDA), tetrahydrocannabinol (THC), including its isomers A6a,10a-tetrahydrocannabinol (A6a,10a-THC), A6a(7)-tetrahydrocannabinol (A6a(7)-THC), A8-tetrahydrocannabinol (A8-THC), A9-tetrahydrocannabinol (A9-THC), A10-tetrahydrocannabinol (A10-THC), A9,11 -tetrahydrocannabinol (A9,11-THC), tetrahydrocannabinolic acid (THCA), cannabinol (CBN), cannabinolic acid (CBNA), and cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocan nabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), and cannabigerol monomethyl ether (CBGM).
[0044] In one embodiment, the first cannabinoid is selected from any one of THCV, CBD, and CBC. In one embodiment, the first cannabinoid is THCV. In one embodiment, the first cannabinoid is CBD. In one embodiment, the first cannabinoid is CBC.
[0045] In one embodiment, the second cannabinoid is selected from any one of THC. In one embodiment, the second cannabinoid is THC.
[0046] In one embodiment, the first cannabinoid is THCV and the second cannabinoid is THC. In one embodiment, the first cannabinoid is CBD and the second cannabinoid is THC. cannabinoids.WBDRef.No. B118615 1980WO (00125)
[0047] ln one embodiment, the first cannabinoid is CBC and the second cannabinoid is CBD. cannabinoids.
[0048] The method described herein enables remediation of a second cannabinoid from a starting formulation comprising a first cannabinoid and the second cannabinoid, wherein the first and second cannabinoid have at least one of similar chemical structures, similar polarities and / or similar logP values. Without being bound by theory, a first and second cannabinoid having these properties may be difficult to separate by other known separation methods.
[0049] LogP is the partition coefficient of a molecule between non-aqueous phases and aqueous, usually considered as octanol and water. References herein to LogP are based on an octanol / water partition. A logP value may therefore indicate the hydrophobicity of a compound. In particular, it can be used as an approximation for polarity. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 2.0. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 1.9. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 1.8. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 1.7. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 1.6. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 1.5. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 1.4. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 1.3. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 1.2. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 1.1. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 1.0. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.9. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.8. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.7. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.6. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.5. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.4. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.3. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.2. In one embodiment, the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.1.
[0050] In one embodiment, the first cannabinoid is THCV and the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 1.0. In one embodiment, the first cannabinoid isWBDRef.No. B118615 1980WO (00125)
[0051] THCV and the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.9. In one embodiment, the first cannabinoid is THCV and the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.8. In one embodiment, the first cannabinoid is THCV and the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.7. In one embodiment, the first cannabinoid is THCV and the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.6. In one embodiment, the first cannabinoid is THCV and the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.5. In one embodiment, the first cannabinoid is THCV and the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.4. In one embodiment, the first cannabinoid is THCV and the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.3. In one embodiment, the first cannabinoid is THCV and the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.2. In one embodiment, the first cannabinoid is THCV and the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.1.
[0052] In one embodiment, the first cannabinoid is present in the starting formulation in an amount of at least 50w / w% based on the total weight of the starting formulation. In one embodiment, the first cannabinoid is present in the starting formulation in an amount of at least 60w / w% based on the total weight of the starting formulation. In one embodiment, the first cannabinoid is present in the starting formulation in an amount of at least 65w / w% based on the total weight of the starting formulation.
[0053] In one embodiment, the first cannabinoid is present in the starting formulation in an amount of less than 90w / w% based on the total weight of the starting formulation. In one embodiment, the first cannabinoid is present in the starting formulation in an amount of from 50 to 90w / w% based on the total weight of the starting formulation. In one embodiment, the first cannabinoid is present in the starting formulation in an amount of from 60 to 90w / w% based on the total weight of the starting formulation. In one embodiment, the first cannabinoid is present in the starting formulation in an amount of from 65 to 90w / w% based on the total weight of the starting formulation.
[0054] In one embodiment, the first cannabinoid is present in the starting formulation in an amount of less than 80w / w% based on the total weight of the starting formulation. In one embodiment, the first cannabinoid is present in the starting formulation in an amount of from 50 to 85w / w% based on the total weight of the starting formulation. In one embodiment, the first cannabinoid is present in the starting formulation in an amount of from 50 to 80w / w% based on the total weight of the starting formulation. In one embodiment, the first cannabinoid is present in the starting formulation in an amount of from 60 to 80w / w% based on the total weight of the starting formulation. In one embodiment, the first cannabinoid is present in the starting formulation in an amount of from 65 to 80w / w% based on the total weight of the starting formulation.WBDRef.No. B118615 1980WO (00125)
[0055] ln one embodiment, the first cannabinoid is present in the starting formulation in an amount of less than 75w / w% based on the total weight of the starting formulation. In one embodiment, the first cannabinoid is present in the starting formulation in an amount of from 50 to 75w / w% based on the total weight of the starting formulation. In one embodiment, the first cannabinoid is present in the starting formulation in an amount of from 60 to 75w / w% based on the total weight of the starting formulation. In one embodiment, the first cannabinoid is present in the starting formulation in an amount of from 65 to 75w / w% based on the total weight of the starting formulation.
[0056] In one embodiment, the second cannabinoid is present in the starting formulation in an amount of at least 1w / w% based on the total weight of the starting formulation. In one embodiment, the second cannabinoid is present in the starting formulation in an amount of at least 2w / w% based on the total weight of the starting formulation. In one embodiment, the second cannabinoid is present in the starting formulation in an amount of at least 3w / w% based on the total weight of the starting formulation. In one embodiment, the second cannabinoid is present in the starting formulation in an amount of at least 4w / w% based on the total weight of the starting formulation. In one embodiment, the second cannabinoid is present in the starting formulation in an amount of at least 5w / w% based on the total weight of the starting formulation. In one embodiment, the second cannabinoid is present in the starting formulation in an amount of at least 10w / w% based on the total weight of the starting formulation. In one embodiment, the second cannabinoid is present in the starting formulation in an amount of at least 15w / w% based on the total weight of the starting formulation.
[0057] In one embodiment, the second cannabinoid is present in the starting formulation in an amount of less than 30w / w% based on the total weight of the starting formulation. In one embodiment, the second cannabinoid is present in the starting formulation in an amount of from 1 to 30w / w% based on the total weight of the starting formulation. In one embodiment, the second cannabinoid is present in the starting formulation in an amount of from 5 to 30w / w% based on the total weight of the starting formulation. In one embodiment, the second cannabinoid is present in the starting formulation in an amount of from 10 to 30w / w% based on the total weight of the starting formulation. In one embodiment, the second cannabinoid is present in the starting formulation in an amount of from 15 to 30w / w% based on the total weight of the starting formulation.
[0058] In one embodiment, the second cannabinoid is present in the starting formulation in an amount of less than 20w / w% based on the total weight of the starting formulation. In one embodiment, the second cannabinoid is present in the starting formulation in an amount of from 5 to 20w / w% based on the total weight of the starting formulation. In one embodiment, the second cannabinoid is present in the starting formulation in an amount of from 10 to 20w / w% based on the total weight of the starting formulation. In one embodiment, the second cannabinoid is present inWBDRef.No. B118615 1980WO (00125)
[0059] the starting formulation in an amount of from 15 to 20w / w% based on the total weight of the starting formulation.
[0060] In one embodiment, the first cannabinoid is present in the staring formulation in an amount greater than that of the second cannabinoid. In one embodiment, the weight ratio of the first cannabinoid to the second cannabinoid in the starting formulation is from 60:40 to 90:10. In one embodiment, the weight ratio of the first cannabinoid to the second cannabinoid in the starting formulation is from 70:30 to 85:15. In one embodiment, the weight ratio of the first cannabinoid to the second cannabinoid in the starting formulation is from 75:25 to 80:20. As will be appreciated by one skilled in the art, the weight ratio of the first cannabinoid to the second cannabinoid is provided relative to each of the two materials and is irrespective of the presence of other materials.
[0061] In one embodiment, the starting formulation is obtained from a phytocannabinoid producing plant. In one embodiment, the first cannabinoid is dominantly produced in the phytocannabinoid producing plant relative to the second cannabinoid. Obtaining the starting formulation from a phytocannabinoid producing plant wherein the first cannabinoid is dominantly produced in the phytocannabinoid producing plant relative to the second cannabinoid may be advantageous in producing materials comprising the remediated formulation comprising the first cannabinoid, particularly where the first cannabinoid is usually a minor cannabinoid occurring in the Cannabis sativa plant. In one embodiment, THCV is dominantly produced in the phytocannabinoid producing plant relative to THC. An example of a suitable strain where THCV is produced dominantly is AT-4002 #047.
[0062] In one embodiment, the starting formulation is extracted from a phytocannabinoid producing plant. In one embodiment, the starting formulation is extracted from a phytocannabinoid producing plant using a CO2extraction process. In one embodiment, the CO2utilized in the extraction process is supercritical.
[0063] The starting formulation may be subjected to a purification step after extraction but before being remediated. In one embodiment, the starting formulation is subjected to winterization and / or short-path distillation after extraction but before being remediated. In one embodiment, the starting formulation is subjected to winterization after extraction but before being remediated. In one embodiment, the starting formulation is subjected to short-path distillation after extraction but before being remediated. In one embodiment, the starting formulation is subjected to winterization and then short-path distillation after extraction but before being remediated. In one embodiment, the starting formulation is subjected to short-path distillation and then winterization after extraction but before being remediated.
[0064] Reverse Phase Flash Chromatography
[0065] The starting formulation comprising the first cannabinoid and a second cannabinoid is remediated via reverse phase flash chromatography.WBDRef.No. B118615 1980WO (00125)
[0066] Reverse phase flash chromatography is generally understood to be a mode of liquid chromatography utilizing a non-polar stationary phase and polar mobile phase for the separation of organic compounds.
[0067] In reverse phase flash chromatography, the stationary phase is typically packed within a column and includes silica gel particles with non-polar groups bonded on the surface. The nonpolar group may be selected from C18 alkyl, C8 alkyl, C4 alkyl, and phenyl groups. In one embodiment, the stationary phase utilized in the reverse phase flash chromatography comprises C18 bonded silica gel particles.
[0068] In one embodiment, the silica gel particle size used in the reverse phase flash chromatography is from 1 to 100 pm. In one embodiment, the silica gel particle size used in the reverse phase flash chromatography is from 5 to 90 pm. In one embodiment, the silica gel particle size used in the reverse phase flash chromatography is from 10 to 70 pm. In one embodiment, the silica gel particle size used in the the reverse phase flash chromatography is from 15 to 50 pm.
[0069] In one embodiment, the stationary phase utilized in the reverse phase flash chromatography is C18 bonded silica gel particles with a silica gel particle size from 15 to 50 pm. In one embodiment, the stationary phase utilized in the reverse phase flash chromatography is C18 bonded silica gel particles with a silica gel particle size of 15 pm. In one embodiment, the stationary phase utilized in the reverse phase flash chromatography is C18 bonded silica gel particles with a silica gel particle size of 50 pm.
[0070] In one embodiment, one or more columns comprising the stationary phase is utilized in the reverse phase flash chromatography. In one embodiment, one column comprising the stationary phase is utilized in the reverse phase flash chromatography. In one embodiment, two or more columns comprising the stationary phase are utilized in the reverse phase flash chromatography. Where two or more columns are present, the columns may be stacked vertically.
[0071] In one embodiment, two or more columns comprising C18 bonded silica gel particles with a silica gel particle size from 15 to 50 pm are utilized in the reverse phase flash chromatography, wherein the columns are stacked vertically.
[0072] In one embodiment, the mobile phase utilized in the reverse phase flash chromatography comprises water and at least one polar organic solvent. Polar organic solvents include but are not limited to methanol, ethanol, isopropanol, acetonitrile, acetone, and tetrahydrofuran (THF). In one embodiment, the mobile phase utilized in the reverse phase flash chromatography comprises water and at least one of methanol, acetonitrile, or ethanol. In one embodiment, the mobile phase utilized in the reverse phase flash chromatography comprises water and methanol. In one embodiment, the mobile phase utilized in the reverse phase flash chromatography comprises water and acetonitrile. In one embodiment, the mobile phase utilized in the reverse phase flash chromatography comprises water and ethanol.WBDRef.No. B118615 1980WO (00125)
[0073] In one embodiment, the mobile phase comprises from about 5% to about 30w / w% water by weight of the mobile phase and from about 95% to about 70w / w% polar organic solvent by weight of the mobile phase. In one embodiment, the mobile phase comprises from about 10% to about 25w / w% water by weight of the mobile phase and from about 90% to about 75w / w% polar organic solvent by weight of the mobile phase. In one embodiment, the mobile phase comprises from about 15% to about 20w / w% water by weight of the mobile phase and from about 85% to about 80w / w% polar organic solvent by weight of the mobile phase. In one embodiment, the mobile phase comprises 20w / w% water by weight of the mobile phase and 80w / w% polar organic solvent by weight of the mobile phase.
[0074] In one embodiment, the mobile phase comprises from about 5% to about 30w / w% water by weight of the mobile phase and from about 95% to about 70w / w% methanol by weight of the mobile phase. In one embodiment, the mobile phase comprises from about 10% to about 25w / w% water by weight of the mobile phase and from about 90% to about 75w / w% methanol by weight of the mobile phase. In one embodiment, the mobile phase comprises from about 15% to about 20w / w% water by weight of the mobile phase and from about 85% to about 80w / w% methanol by weight of the mobile phase. In one embodiment, the mobile phase comprises 20w / w% water by weight of the mobile phase and 80w / w% methanol by weight of the mobile phase.
[0075] The composition of the mobile phase may change over the course of the reverse phase flash chromatography in order to elute the remediated formulation. In one embodiment, the mobile phase is 70w / w% polar organic solvent by weight of the mobile phase at the start of the reverse phase flash chromatography and increases to 100w / w% polar organic solvent by weight of the mobile phase at or before the end of the reverse phase flash chromatography. In one embodiment, the mobile phase is 80w / w% polar organic solvent by weight of the mobile phase at the start of the reverse phase flash chromatography and increases to 100w / w% polar organic solvent by weight of the mobile phase at or before the end of the reverse phase flash chromatography. In one embodiment, the mobile phase is 70w / w% methanol by weight of the mobile phase at the start of the reverse phase flash chromatography and increases to 100w / w% methanol by weight of the mobile phase at or before the end of the reverse phase flash chromatography. In one embodiment, the mobile phase is 80w / w% methanol by weight of the mobile phase at the start of the reverse phase flash chromatography and increases to 100w / w% methanol by weight of the mobile phase at or before the end of the reverse phase flash chromatography. In one embodiment, the mobile phase comprises 20w / w% water by weight of the mobile phase and 80w / w% methanol by weight of the mobile phase during at least part of the reverse phase flash chromatography. In one embodiment, the mobile phase comprises 20w / w% water by weight of the mobile phase and 80w / w% methanol by weight of the mobile phase during the majority of the reverse phase flash chromatography.WBDRef.No. B118615 1980WO (00125)
[0076] Alternatively, the composition of the mobile phase may remain unchanged over the course of the reverse phase flash chromatography in order to elute the remediated formulation. In one embodiment, the mobile phase is 80w / w% polar organic solvent by weight of the mobile phase and 20w / w% water by weight of the mobile phase during the entire process of the reverse phase flash chromatography. In one embodiment, the mobile phase is 80w / w% methanol by weight of the mobile phase and 20w / w% water by weight of the mobile phase during the entire process of the reverse phase flash chromatography. In one embodiment, the mobile phase is 80w / w% ethanol by weight of the mobile phase and 20w / w% water by weight of the mobile phase during the entire process of the reverse phase flash chromatography. In one embodiment, the mobile phase is 80w / w% acetonitrile by weight of the mobile phase and 20w / w% water by weight of the mobile phase during the entire process of the reverse phase flash chromatography.
[0077] In one embodiment, the starting formulation is loaded into the reverse phase flash chromatography in an amount of 100g or less per cycle. In one embodiment, the starting formulation is loaded into the reverse phase flash chromatography in an amount of 50g or less per cycle. In one embodiment, the starting formulation is loaded into the reverse phase flash chromatography in an amount of 20g or less per cycle. In one embodiment, the starting formulation is loaded into the reverse phase flash chromatography in an amount of 10g or less per cycle. In one embodiment, the starting formulation is loaded into the reverse phase flash chromatography in an amount of 5g or less per cycle. In one embodiment, the starting formulation is loaded into the reverse phase flash chromatography in an amount of 3g or less per cycle. In one embodiment, the starting formulation is loaded into the reverse phase flash chromatography in an amount dependent on the silica gel particle size of the stationary phase. In one embodiment, the starting formulation is loaded into the reverse phase flash chromatography in an amount of 100g or less per cycle, when the stationary phase has a silica gel particle size of 50pm.
[0078] In one embodiment, the flow rate utilized in the reverse phase flash chromatography is from 10 to 250 ml / min. In one embodiment, the flow rate utilized in the reverse phase flash chromatography is from 50 to 150 ml / min. In one embodiment, the flow rate utilized in the reverse phase flash chromatography is from 140 to 150 ml / min. In particular, the flow rate utilized in the reverse phase flash chromatography is around 30 ml / min when bonded silica gel particles with a silica gel particle size of 15 pm are used in the column.
[0079] In one embodiment, the flow rate utilized in the reverse phase flash chromatography may be dependent on the silica gel particle size of the stationary phase. In one embodiment, the flow rate utilized in the reverse phase flash chromatography may be from 120 to 170 ml / min, when the stationary phase has a silica gel particle size of 50pm. In one embodiment, the flow rate utilized in the reverse phase flash chromatography may be from 140 to 150 ml / min, when the stationary phase has a silica gel particle size of 50pm. In one embodiment, the flow rate utilized in theWBDRef.No. B118615 1980WO (00125)
[0080] reverse phase flash chromatography may be from 140 to 145 ml / min, when the stationary phase has a silica gel particle size of 50pm.
[0081] Depending on the relative polarity of the first and second cannabinoids, they will elute out of the reverse phase flash chromatography apparatus at different times. The skilled person is able to perform a test run on the starting formulation so as to determine the elution fractions generated for any particular column configuration, flow rate and stationary phase. Once the fractions containing the first cannabinoid have been identified, a further sample of the starting material can be processed via the apparatus.
[0082] In one embodiment, the first cannabinoid elutes from the apparatus before the second cannabinoid.
[0083] In one embodiment, the first cannabinoid is collected when the reverse phase flash chromatography cycle has been running for at least 5 minutes. In one embodiment, the first cannabinoid is collected when the reverse phase flash chromatography cycle has been running for at least 6 minutes. In one embodiment, the first cannabinoid is collected when the reverse phase flash chromatography cycle has been running for at least 7 minutes. In one embodiment, the first cannabinoid is collected when the reverse phase flash chromatography cycle has been running for at least 8 minutes. In one embodiment, the first cannabinoid is collected when the reverse phase flash chromatography cycle has been running for at least 9 minutes. In one embodiment, the first cannabinoid is collected when the reverse phase flash chromatography cycle has been running for at least 10 minutes.
[0084] In one embodiment, the first cannabinoid is collected when the reverse phase flash chromatography cycle has been running for less than 20 minutes. In one embodiment, the first cannabinoid is collected when the reverse phase flash chromatography cycle has been running for less than 19 minutes. In one embodiment, the first cannabinoid is collected when the reverse phase flash chromatography cycle has been running for less than 18 minutes. In one embodiment, the first cannabinoid is collected when the reverse phase flash chromatography cycle has been running for less than 17 minutes. In one embodiment, the first cannabinoid is collected when the reverse phase flash chromatography cycle has been running for less than 16 minutes. In one embodiment, the first cannabinoid is collected when the reverse phase flash chromatography cycle has been running for less than 15 minutes.
[0085] As described above, the reverse phase flash chromatography utilizes water and polar organic solvents. These solvents may need to be removed from the remediated formulation following reverse phase flash chromatography. In one embodiment, the remediated formulation produced from the reverse phase flash chromatography is subjected to solvent evaporation. In one embodiment, the remediated formulation is produced directly from the reverse phase flash chromatography without further purification. In one embodiment, the remediated formulation produced from the reverse phase flash chromatography is subjected to furtherWBDRef.No. B118615 1980WO (00125)
[0086] purification. In one embodiment, the remediated formulation produced from the reverse phase flash chromatography is subjected to further reverse phase flash column chromatography as described herein and / or distillation.
[0087] Remediated Formulation
[0088] Remediation of the second cannabinoid using the method described herein allows production of a remediated formulation with low amounts of the second cannabinoid. Such a formulation is desirable where the second cannabinoid has a physiological effect which is less desired in a particular consumer product. This may be because the consumer product in question aims to deliver a specific physiological effect and thus having multiple different cannabinoids with their associated varying effects may not be desirable. It may also be that the chemical stability of the second cannabinoid is undesirable and so removing it can lead to shelf life advantages. It may also be that certain cannabinoids are regulated, perhaps due to their medicinal effects, and thus it might be desirable to remove these cannabinoids so as to comply with regulation.
[0089] In one embodiment, the first cannabinoid is present in the remediated formulation in an amount of at least 80w / w% based on the total weight of the remediated formulation. In one embodiment, the first cannabinoid is present in the remediated formulation in an amount of at least 90w / w% based on the total weight of the remediated formulation. In one embodiment, the first cannabinoid is present in the remediated formulation in an amount of at least 95w / w% based on the total weight of the remediated formulation.
[0090] In one embodiment, the first cannabinoid is present in the remediated formulation in an amount of less than 99w / w% based on the total weight of the remediated formulation. In one embodiment, the first cannabinoid is present in the remediated formulation in an amount of from 80 to 99w / w% based on the total weight of the remediated formulation. In one embodiment, the first cannabinoid is present in the remediated formulation in an amount of from 90 to 99w / w% based on the total weight of the remediated formulation. In one embodiment, the first cannabinoid is present in the remediated formulation in an amount of from 95 to 99w / w% based on the total weight of the remediated formulation.
[0091] In one embodiment, the second cannabinoid is present in the remediated formulation in an amount of less than 0.5w / w% based on the total weight of the remediated formulation. In one embodiment, the second cannabinoid is present in the remediated formulation in an amount of less than 0.3w / w% based on the total weight of the remediated formulation. In one embodiment, the second cannabinoid is present in the remediated formulation in an amount of less than 0.2w / w% based on the total weight of the remediated formulation. In one embodiment, the second cannabinoid is present in the remediated formulation in an amount of less than 0.1w / w% based on the total weight of the remediated formulation.WBDRef.No. B118615 1980WO (00125)
[0092] In one embodiment, the weight ratio of the first cannabinoid to the second cannabinoid in the remediated formulation is from 10:1 to 300:1. In one embodiment, the weight ratio of the first cannabinoid to the second cannabinoid in the remediated formulation is from 50:1 to 300:1. In one embodiment, the weight ratio of the first cannabinoid to the second cannabinoid in the remediated formulation is from 100:1 to 300:1. As will be appreciated by one skilled in the art, the weight ratio of the first cannabinoid to the second cannabinoid is provided relative to each of the two materials and is irrespective of the presence of other materials.
[0093] Aerosolisable material
[0094] The remediated formulation described herein may be used in an aerosolisable material. In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 0.1 to 70 w / w% based on the total weight of the aerosolisable material. In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 0.5 to 70 w / w% based on the total weight of the aerosolisable material. In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 1 to 70 w / w% based on the total weight of the aerosolisable material. In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 2 to 70 w / w% based on the total weight of the aerosolisable material.
[0095] In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 3 to 70 w / w% based on the total weight of the aerosolisable material. In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 4 to 70 w / w% based on the total weight of the aerosolisable material. In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 5 to 70 w / w% based on the total weight of the aerosolisable material.
[0096] In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 0.1 to 65 w / w% based on the total weight of the aerosolisable material. In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 0.1 to 60 w / w% based on the total weight of the aerosolisable material. In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 0.1 to 55 w / w% based on the total weight of the aerosolisable material. In oneWBDRef.No. B118615 1980WO (00125)
[0097] embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 0.1 to 50 w / w% based on the total weight of the aerosolisable material. In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 0.1 to 45 w / w% based on the total weight of the aerosolisable material. In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 0.1 to 40 w / w% based on the total weight of the aerosolisable material. In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 0.1 to 35 w / w% based on the total weight of the aerosolisable material. In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 0.1 to 30 w / w% based on the total weight of the aerosolisable material. In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 0.1 to 25 w / w% based on the total weight of the aerosolisable material. In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 0.1 to 20 w / w% based on the total weight of the aerosolisable material. In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 0.1 to 15 w / w% based on the total weight of the aerosolisable material. In one embodiment, the aerosolisable material may comprise the remediated formulation so as to provide the first cannabinoid in the aerosolisable material in an amount of from 0.1 to 10 w / w% based on the total weight of the aerosolisable material.
[0098] In one embodiment, the aerosolisable material further comprises one or more aerosol forming materials capable of forming an aerosol, particularly when evaporated and allowed to condense. In some embodiments, the aerosol forming material comprises one or more of propylene glycol, glycerol, triethylene glycol, tetraethylene glycol, 1,3-butylene glycol, erythritol, meso-Erythritol, ethyl vanillate, ethyl laurate, a diethyl suberate, triethyl citrate, triethylene glycol diacetate, triacetin, a diacetin mixture, benzyl benzoate, benzyl phenyl acetate, tributyrin, lauryl acetate, lauric acid, myristic acid, and propylene carbonate.
[0099] In one embodiment, the total amount of aerosol forming material is 55 %w / w or more based on the total weight of the formulation. In one embodiment, the total amount of aerosol forming material is 60 %w / w or more based on the total weight of the formulation. In one embodiment, the total amount of aerosol forming material is 65 %w / w or more based on the total weight of the formulation. In one embodiment, the total amount of aerosol forming material is 70 %w / w or more based on the total weight of the formulation. In one embodiment, the total amountWBDRef.No. B118615 1980WO (00125)
[0100] of aerosol forming material is 75 %w / w or more based on the total weight of the formulation. In one embodiment, the total amount of aerosol forming material is 80 %w / w or more based on the total weight of the formulation. In one embodiment, the total amount of aerosol forming material is 85 %w / w or more based on the total weight of the formulation. In one embodiment, the total amount of aerosol forming material is 90 %w / w or more based on the total weight of the formulation. In one embodiment, the total amount aerosol forming material is 95 %w / w or more based on the total weight of the formulation.
[0101] In one embodiment, the aerosol forming material comprises propylene glycol. In one embodiment, the aerosol forming material comprises glycerol. In one embodiment, both glycerol and propylene glycol are present as carrier constituents. In one embodiment, both glycerol and propylene glycol are present as aerosol forming materials.
[0102] In one embodiment, the aerosol forming material comprises triethyl citrate.
[0103] The aerosolisable material may comprise one or more further constituents. In particular, one or more further constituents may be selected from one or more physiologically and / or olfactory active constituents, and / or one or more functional constituents.
[0104] In some embodiments, the active constituent is a physiologically active constituent and may be selected from nicotine, nicotine salts (e.g. nicotine ditartrate / nicotine bitartrate), nicotine-free tobacco substitutes, other alkaloids such as caffeine, or mixtures thereof.
[0105] In some embodiments, the active constituent is an olfactory active constituent and may be selected from a "flavour" and / or "flavourant" which, where local regulations permit, may be used to create a desired taste, aroma or sensation in a product for adult consumers. In some instances such constituents may be referred to as flavours, flavourants, cooling agents, heating agents, or sweetening agents, and may include one or more of extracts (e.g., liquorice, hydrangea, Japanese white bark magnolia leaf, chamomile, fenugreek, clove, menthol, Japanese mint, aniseed, cinnamon, herb, Wintergreen, cherry, berry, peach, apple, Drambuie, bourbon, scotch, whiskey, spearmint, peppermint, lavender, cardamom, celery, cascarilla, nutmeg, sandalwood, bergamot, geranium, honey essence, rose oil, vanilla, lemon oil, orange oil, cassia, caraway, cognac, jasmine, ylang-ylang, sage, fennel, piment, ginger, anise, coriander, coffee, or a mint oil from any species of the genus Mentha), flavour enhancers, bitterness receptor site blockers, sensorial receptor site activators or stimulators, sugars and / or sugar substitutes (e.g., sucralose, acesulfame potassium, aspartame, saccharine, cyclamates, lactose, sucrose, glucose, fructose, sorbitol, or mannitol), and other additives such as charcoal, chlorophyll, minerals, botanicals, or breath freshening agents. They may be imitation, synthetic or natural ingredients or blends thereof. They may be in any suitable form, for example, oil, liquid, or powder.
[0106] The one or more other functional constituents may comprise one or more of pH regulators, colouring agents, and / or preservatives.WBDRef.No. B118615 1980WO (00125)
[0107] In particular, the pH regulator may include one or more acids selected from organic or inorganic acids. An example of an inorganic acid is phosphoric acid. The organic acid may include a carboxylic acid. The carboxylic acid may be any suitable carboxylic acid. In one embodiment the acid is a mono-carboxylic acid. In one embodiment the acid may be selected from the group consisting of ascorbic acid, acetic acid, lactic acid, formic acid, citric acid, benzoic acid, pyruvic acid, levulinic acid, succinic acid, tartaric acid, oleic acid, sorbic acid, propionic acid, phenylacetic acid, and mixtures thereof.
[0108] In some embodiments, the aerosolisable formulation is in liquid form. In some embodiments, the aerosolisable formulation is not in liquid form. In some embodiments, the aerosolisable formulation is in the form of a gel or paste.
[0109] In some embodiments, the aerosolisable formulation may contain two or more different remediated formulations wherein the first cannabinoid in each of the remediated formulations is different. This can be advantageous where a precise blend of different first cannabinoids is desired in the aerosolisable formulation.
[0110] Inqestible material
[0111] The remediated formulation described herein may be used in an ingestible material.
[0112] The ingestible material may be in the form of a tincture, beverage, chew, tablet, pastille, gum, melt or lozenge.
[0113] In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0001 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0005 to 1 .0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.001 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0015 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.002 to 1 .0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0025 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.003 to 1 .0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0035 to 1.0w / w% based on the total weight of theWBDRef.No. B118615 1980WO (00125)
[0114] ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.004 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0045 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.005 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0055 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.006 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0065 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.007 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0075 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.008 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0085 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.009 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0095 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.01 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.05 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.1 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.2 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation soWBDRef.No. B118615 1980WO (00125)
[0115] as to provide the first cannabinoid in an amount of from 0.3 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.4 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.5 to 1.0w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0001 to 0.9w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0001 to 0.8w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0001 to 0.7w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0001 to 0.6w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0001 to 0.5w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0001 to 0.4w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0001 to 0.3w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0001 to 0.2w / w% based on the total weight of the ingestible material. In one embodiment, the ingestible material may comprise the remediated formulation so as to provide the first cannabinoid in an amount of from 0.0001 to 0.1w / w% based on the total weight of the ingestible material.
[0116] The ingestible material may further comprise one or more of selected from emulsifiers, sweeteners, salts, flavors, binders, preservatives, colorants, and combinations thereof.
[0117] Accordingly, in some embodiments, the remediated formulation is combined with one or more emulsifiers to form an emulsion. The emulsion may then be combined with other materials so as to form the ingestible material.
[0118] In some embodiments, the emulsion comprises one or more emulsifiers. The emulsifier may be selected from lecithin, tocophorel (vitamin E), sodium laurel sulphate (SLS), or mixtures thereof.
[0119] In some embodiments, the ingestible material comprises a salt (e.g., an alkali metal salt), typically employed in an amount sufficient to provide desired sensory attributes to the composition. Non-limiting examples of suitable salts include sodium chloride, potassium chloride, ammoniumWBDRef.No. B118615 1980WO (00125)
[0120] chloride, flour salt, sodium acetate, sodium citrate, calcium citrate, and the like. In some embodiments, the salt is sodium chloride, ammonium chloride, or a combination thereof. In some embodiments, the salt is tri-sodium citrate, calcium citrate, or a combination thereof.
[0121] When present, a representative amount of salt is about 0.1% by weight or more, about 0.5% by weight or more, about 1.0% by weight or more, or about 1.5% by weight or more, but will typically make up about 10% or less of the total weight of the product, or about 7.5% or less, or about 5% or less (e.g., from about 0.1 to about 5% by weight).
[0122] In order to improve the sensory properties of the ingestible material according to the disclosure, one or more sweeteners may be added. The sweeteners can be any sweetener or combination of sweeteners, in natural or artificial form, or as a combination of natural and artificial sweeteners. Examples of natural sweeteners include fructose, sucrose, glucose, maltose, isomaltulose, mannose, galactose, lactose, allulose, soluble tapioca fiber, inulin, stevia, honey, and the like. Examples of artificial sweeteners include sucralose, maltodextrin, saccharin, aspartame, acesulfame K, neotame, and the like.
[0123] In some embodiments, the sweetener comprises one or more sugar alcohols. Sugar alcohols are polyols derived from monosaccharides or disaccharides that have a partially or fully hydrogenated form. Sugar alcohols have, for example, about 4 to about 20 carbon atoms and include erythritol, arabitol, ribitol, isomalt, maltitol, dulcitol, iditol, mannitol, xylitol, lactitol, sorbitol, and combinations thereof (e.g., hydrogenated starch hydrolysates). In some embodiments, the sweetener is sucralose, acesulfame K, or a combination thereof.
[0124] When present, a sweetener or combination of sweeteners may make up from about 0.01 to about 20% or more of the product by weight, for example, from about 0.01 to about 0.1 , from about 0.1 to about 1%, from about 1 to about 5%, from about 5 to about 10%, or from about 10 to about 20% by weight, based on the total weight of the product. In some embodiments, a combination of sweeteners is present at a concentration of from about 0.01% to about 0.1% by weight of the composition, such as about 0.01 , about 0.02, about 0.03, about 0.04, about 0.05, about 0.06, about 0.07, about 0.08, about 0.09, or about 0.1 % by weight of the product. In some embodiments, a combination of sweeteners is present at a concentration of from about 0.1% to about 0.5% by weight of the composition, such as about 0.1 , about 0.2, about 0.3, about 0.4, or about 0.5% by weight of the product. In some embodiments, a combination of sweeteners is present at a concentration of from about 1% to about 3% by weight of the composition.
[0125] In some embodiments, the ingestible material comprises a flavoring agent. As used herein, a "flavoring agent," "flavor" or "flavorant" is any flavorful or aromatic substance capable of altering the sensory characteristics associated with the ingestible product. Examples of sensory characteristics that can be modified by the flavoring agent include taste, mouthfeel, moistness, coolness / heat, and / or fragrance / aroma. Flavoring agents may be natural or synthetic, and the character of the flavors imparted thereby may be described, without limitation, as fresh, sweet,WBDRef.No. B118615 1980WO (00125)
[0126] herbal, confectionary, floral, citrus, fruity, or spicy. Specific types of flavors include, but are not limited to, vanilla, coffee, chocolate / cocoa, cream, mint, spearmint, menthol, peppermint, Wintergreen, eucalyptus, lavender, cardamom, nutmeg, cinnamon, clove, cascarilla, sandalwood, honey, jasmine, ginger, anise, sage, licorice, lemon, orange, apple, peach, lime, cherry, strawberry, trigeminal sensates, terpenes, and any combinations thereof. See also, Leffmgwell et al, Tobacco Flavoring for Smoking Products, R. J. Reynolds Tobacco Company (1972), which is incorporated herein by reference.
[0127] Flavoring agents also may include components that are considered moistening, cooling or smoothening agents, such as eucalyptus. These flavors may be provided neat (i.e., alone) or in a composite, and may be employed as concentrates or flavor packages (e.g., spearmint and menthol, orange and cinnamon; lime, pineapple, and the like). Representative types of components also are set forth in US Pat. No. 5,387,416 to White et al; US Pat. App. Pub. No. 2005 / 0244521 to Strickland et al; and PCT Application Pub. No. WO 05 / 041699 to Quinter et al, each of which is incorporated herein by reference. In some instances, the flavoring agent may be provided in a spray-dried form or a liquid form.
[0128] The amount of flavoring agent utilized in the material can vary, but is typically up to about 10% by weight, and certain embodiments are characterized by a flavoring agent content of at least about 0.1% by weight, such as about 0.5 to about 10%, about 1 to about 5%, or about 2 to about 4% weight, based on the total weight of the composition.
[0129] A binder (or combination of binders) may be employed in certain embodiments, in amounts sufficient to provide the desired physical attributes and physical integrity to the ingestible material, and binders also often function as thickening or gelling agents. Typical binders can be organic or inorganic, ora combination thereof. Representative binders include cellulose derivatives (e.g., cellulose ethers), povidone, gelatin, sodium alginate, starch-based binders, pectin, gums, carrageenan, pullulan, zein, and the like, and combinations thereof.
[0130] In some embodiments, the binder comprises pectin or carrageenan or combinations thereof.
[0131] The amount of binder utilized in the material can vary based on the binder and the desired product properties, but is typically up to about 30% by weight, and certain embodiments are characterized by a binder content of at least about 0.1% by weight, such as about 0.5 to about 30% by weight, or about 1 to about 10% by weight, based on the total weight of the product.
[0132] In certain embodiments, the binder includes a gum, for example, a natural gum. As used herein, a natural gum refers to polysaccharide materials of natural origin that have binding properties, and which are also useful as a thickening or gelling agents. Representative natural gums derived from plants, which are typically water soluble to some degree, include xanthan gum, guar gum, gum arabic, ghatti gum, gum tragacanth, karaya gum, locust bean gum, gellan gum, and combinations thereof. When present, natural gum binder materials are typically present in anWBDRef.No. B118615 1980WO (00125)
[0133] amount of up to about 5% by weight, for example, from about 0.1 , about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, or about 1 %, to about 2, about 3, about 4, or about 5% by weight, based on the total weight of the product.
[0134] In some embodiments, the binder comprises pectin. Pectins are natural polymers related to carbohydrates and which are acidic heteropolysaccharides (polysaccharides comprising multiple monosaccharide units). As opposed to carbohydrates, the pectin C-6 position contains a carboxylic acid (or corresponding methyl ester or carboxamide) group instead of a hydroxymethyl group. The principal subunit is known as galacturonic acid, which can be copolymerized with L-rhamnose. Other sugars are featured as side-chain substituents. Pectin acts as a thickening and gelling agent. Pectin isolated from sources such as apple pomace, citrus peels, sugarbeet waste from sugar manufacturing, sunflower heads discarded from seed harvesting, mango waste, and other commercially available pectins may be used. In combination with certain sugars, under acidic conditions (e.g., a pH of from about 2.5 to about 5), or in the presence of a gelation agent (calcium or other divalent alkaline earth elements), pectins may provide a gel or gum consistency to compositions as disclosed herein. In some embodiments, the binder comprises low methoxy pectin. Suitable low methoxy pectins include, for example, "GENU® pectin type LM-104 AS", available from CP Kelco, Atlanta, GA, USA. In some embodiments, the binder comprises low methoxy pectin in combination with a gelation agent. In some embodiments, the gelation agent comprises calcium ions, such as, but not limited to, calcium diphosphate. In some embodiments, the binder comprises a high methoxy pectin in combination with an organic acid, described herein below. In some embodiments, the binder comprises a high methoxy pectin in combination with citric acid.
[0135] When present, a pectin binder is typically present in an amount of up to about 3% by weight, for example, from about 0.1 , about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, or about 1 , to about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8. about 1.9, about 2, about 2.1 , about 2.2, about 2.3. about 2.4, about 2.5, about 2.6, about 2.7, about 2.8, about 2.9, or about 3% by weight, based on the total weight of the product.
[0136] In some embodiments, combinations of binders may be used, such as various combinations of starches, pectins, carrageenans, agar, gums, and the like, in order to provide desired attributes to the oral product, to enhance processing ability, or both. Examples of desired attributes include, but are not limited to, mouth feel, texture, firmness, chewability, and dissolution rate.
[0137] A colorant may be employed in amounts sufficient to provide the desired physical attributes to the material. Examples of colorants include various dyes and pigments, such as caramel coloring and titanium dioxide. Natural colorants such as curcumin, beet juice extract, spirulina; also a variety of synthetic pigments may also be used. The amount of colorant utilized in the productWBDRef.No. B118615 1980WO (00125)
[0138] can vary, but when present is typically up to about 3% by weight, such as from about 0.1%, about 0.5%, or about 1%, to about 3% by weight, based on the total weight of the product.
[0139] Possible preservatives present in the ingestible material include sodium benzoate, potassium sorbate and combinations thereof.
[0140] Examples
[0141] Starting material preparation
[0142] Mature cannabis plants are harvested, dried and shredded before being placed in an oven (a process referred to as “decarbing”). The material is then put through supercritical CO2 extraction, resulting in a crude resin. The crude resin is treated with cold ethanol to remove fats and waxes in a process called “winterization”. Winterized resin is then put through short path distillation to improve potency, creating distillate.
[0143] THCV Purification
[0144] The THCV distillate was dissolved in methanol at ratio of 1 :2 w / w, then placed in the -80 freezer for 24 hours. The solution was then filtered through a 0.2 pm PES membrane filter to remove any residual waxes. Using the Interchim Puriflash 5.250, the flash chromatography column (15 pm or 50 pm) is equilibrated with a solvent mixture of 80% methanol and 20% water. The solution was then pumped on to the column through Solvent Line D. Once the solution is completely pumped onto the column, the flow rate is increased to either 30 mL / min (15 pm) or 142 mL / min (50 pm) and the solvent composition is changed to 80% methanol and 20% water for the remainder of the run. Fractions are collected in 25 mL test tubes, with the collection threshold set to anything above 400 mAU. When the run has been completed, the column is either re-calibrated for another run or flushed with methanol for storage.
[0145] Example 1
[0146] In Example 1, a 1.7g starting formulation comprising a first cannabinoid (THCV) and a second cannabinoid (THC) was fed to a reverse phase flash chromatography apparatus (Interchim Puriflash, available from...) via the dedicated solvent line. The parameters for the cycle were as follows:
[0147] Column: 15 pm
[0148] Flow rate: 30mL / min
[0149] Mobile phase: 80% methanol / 20% water
[0150] Various fractions were eluted as shown in Figure 1.WBDRef.No. B118615 1980WO (00125)
[0151] Table 1
[0152] Material THCV% THC%
[0153] Pre-flash Distillate 63.0 21.0
[0154] Post-flash Distillate 84.3 0.7
[0155]
[0156] As can be seen from Table 1 , the post-flash distillate had increased THCV and reduced THC.
[0157] Example 2
[0158] Example 2 was performed as for Example 1 , with the following changes:
[0159] A 5g starting formulation comprising a first cannabinoid (THCV) and a second cannabinoid (THC) was used.
[0160] Column: 15 pm
[0161] Flow rate: 30 mL / min
[0162] Mobile phase: 80% methanol / 20% water
[0163] Various fractions were eluted as shown in Figure 2.
[0164] Table 2
[0165] Material THCV% THC%
[0166] Pre-flash Distillate 63.0 21.0
[0167] Post-flash Distillate 80.2 ND
[0168]
[0169] As can be seen from Table 2, the post-flash distillate had increased THCV and no THC was detected.
[0170] Example 3
[0171] In Example 3, a 50g starting formulation comprising a first cannabinoid (THCV) and a second cannabinoid (THC) was fed to a reverse phase flash chromatography apparatus (Interchim Puriflash, available from...) via the dedicated solvent line. The parameters for the cycle were as follows:
[0172] Column: 50 pm
[0173] Flow rate: 30mL / min
[0174] Mobile phase: 80% methanol / 20% waterWBDRef.No. B118615 1980WO (00125)
[0175] Table 3
[0176] Material THCV% THC%
[0177] Pre-flash Distillate 70.0 15.0
[0178] Post-flash Distillate 85.9 ND
[0179]
[0180] The various embodiments described herein are presented only to assist in understanding and teaching the claimed features. These embodiments are provided as a representative sample of embodiments only, and are not exhaustive and / or exclusive. It is to be understood that advantages, embodiments, examples, functions, features, structures, and / or other aspects described herein are not to be considered limitations on the scope of the invention as defined by the claims or limitations on equivalents to the claims, and that other embodiments may be utilised and modifications may be made without departing from the scope of the claimed invention. Various embodiments of the invention may suitably comprise, consist of, or consist essentially of, appropriate combinations of the disclosed elements, components, features, parts, steps, means, etc., other than those specifically described herein. In addition, this disclosure may include other inventions not presently claimed, but which may be claimed in future.
Claims
WBDRef.No. B118615 1980WO (00125)Claims1. A method of producing a remediated formulation comprising a first cannabinoid, the method comprising remediating a starting formulation comprising the first cannabinoid and a second cannabinoid via reverse phase flash chromatography.
2. The method according to claim 1 , wherein the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 1.5.
3. The method according to claim 2, wherein the first cannabinoid and the second cannabinoid have a logP difference of from 0 to 0.5.
4. The method according to any one of the preceding claims, wherein the first cannabinoid is THCV.
5. The method according to any one of the preceding claims, wherein the second cannabinoid is THC.
6. The method according to any one of the preceding claims, wherein the mobile phase utilized in the reverse phase flash chromatography comprises one or more of water, methanol, acetonitrile, or ethanol.
7. The method according to claim 6, wherein the mobile phase utilized in the reverse phase flash chromatography comprises from about 5% to about 30w / w% water by weight of the mobile phase and from about 95% to about 70w / w% methanol by weight of the mobile phase.
8. The method according to any one of the preceding claims, wherein the flow rate utilized in the reverse phase flash chromatography is 10 to 250 ml / min.
9. The method according to any one of the preceding claims, wherein the starting formulation is loaded into the reverse phase flash chromatography in an amount of 100g or less per cycle, preferably less than 50g or less per cycle.
10. The method according to any one of the preceding claims, wherein the second cannabinoid is present in the remediated formulation in an amount of less than 0.5w / w% based on the total weight of the remediated formulation, preferably less than 0.3w / w% based on the total weight of the remediated formulation, preferably less than 0.2w / w% based on the total weight of the remediated formulation.WBDRef.No. B118615 1980WO (00125)11. The method according to any one of the preceding claims, wherein the second cannabinoid is present in the starting formulation in an amount of at least 5w / w% based on the total weight of the starting formulation, preferably at least 10w / w% based on the total weight of the starting formulation, preferably at least 15w / w% based on the total weight of the starting formulation.
12. The method according to any one of the preceding claims, wherein the starting formulation is extracted from a phytocannabinoid producing plant.
13. The method according to claim 12, wherein the extraction is a CO2 extraction process.
14. The method according to claim 12 or claim 13, wherein the starting formulation is subjected to winterization after extraction but before being remediated via reverse phase flash chromatography.
15. The method according to any one of claims 12 to 14, wherein the first cannabinoid is dominantly produced in the phytocannabinoid producing plant relative to the second cannabinoid.
16. The method according to any one of the preceding claims, wherein the remediated formulation is produced directly from the reverse phase flash chromatography without further purification.
17. The method according to any one of claims 1 to 15, wherein the remediated formulation produced from the reverse phase flash chromatography is subjected to further purification.
18. A remediated formulation obtained or obtainable by the method of any one of the preceding claims.
19. A formulation comprising THCV in an amount of greater than 0.0001 w / w%, wherein the formulation comprises less than 0.5w / w% THC.
20. An aerosolisable material comprising the remediated formulation of claim 18 or the formulation of claim 19.WBDRef.No. B118615 1980WO (00125)21. The aerosolisable material according to claim 20, further comprising one or more aerosol forming materials.
22. An ingestible material comprising the remediated formulation of claim 18 or the formulation of claim 19.
23. The ingestible material according to claim 22, further comprising one or more emulsifiers.
